PAREXEL has appointed four former senior executives from the U.S. Food and Drug Administration (FDA) to its Regulatory Consulting group.  The new additions join more than 60 former global regulators in the group and will be focused on helping companies understand and work within the current FDA and global regulatory climates to optimize drug development and mitigate risk of unnecessary delays. The additions to PAREXEL’s team have broad experience in policy making, including current regulations...